標記臨床研究 XOMA 深 滬
等待開盤 10-03 09:30:00 美东时间
39.54
+0.310
+0.79%
華盛通- 最 高39.75
- 今 開38.84
- 成交量 8.08万股
- 最 低 37.4907
- 昨 收 39.23
- 總市值 4.78亿
- 52周最高 39.75
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 18.352
- 委 比 -86.33%
- 總股本 1208.77万
- 歷史最高 191.40
- 量 比 1.68
- 振 幅 5.76%
- 歷史最低 3.96
- 每 手 1
- 風險率 4.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
XOMA Royalty and LAVA announce the extension of the tender offer for LAVA shares until October 17, 2025, originally set for October 3. The offer includes cash and a contingent value right (CVR) per share. The transaction is expected to close in Q4 2025, subject to 80% (or 75% in certain cases) of shares being tendered, shareholder approval, and other customary conditions. LAVA shareholders who have already tendered shares do not need to re-tender...
10-02 20:43
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
LAVA Therapeutics has canceled its Extraordinary General Meeting (EGM) scheduled for September 30, 2025, to allow further discussions with XOMA Royalty regarding the terms of their proposed transaction. Both companies remain committed to completing the deal, which is now anticipated to close in the fourth quarter of 2025. The EGM will be reconvened by early November, with details to be announced later. The cancellation aims to address potential l...
09-30 11:00
ESSA Pharma cuts shareholder payout in revised Xeno deal
ESSA Pharma (NASDAQ:EPIX) fell above 18% premarket on Wednesday after the company revised terms of its merger with biotech firm XenoTherapeutics, lowering expected shareholder payout due to potential ...
09-24 18:35
ESSA Pharma Amends Agreement With XenoTherapeutics, Shareholders To Receive $0.12 Cash And Up To $0.14 Per CVR
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised termsFurther Adjourns Special Meeting to October 3, 2025
09-24 18:07
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting ...
09-24 18:00
Xoma Completes Acquisition of HilleVax
The latest announcement is out from Xoma ( ($XOMA) ). XOMA Royalty Corporation,...
09-24 05:28
HilleVax Acquired by XOMA, Delisting from Nasdaq
The latest announcement is out from HilleVax, Inc ( ($HLVX) ). HilleVax, Inc. h...
09-17 21:49
快讯 | XOMA Royalty Corp：Benchmark将目标价从35美元上调至50美元
XOMA Royalty Corp : Benchmark Raises Target Price to $50 From $35
09-09 19:39
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
XOMA Royalty Corporation (NASDAQ: XOMA) announced that its CEO, Owen Hughes, and CIO, Brad Sitko, will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 9:00 AM ET. The presentation will be available via webcast at https://bit.ly/4mjFgkY and through the investor relations section on XOMA's website at www.xoma.com. XOMA Royalty is a biotech royalty aggregator that acquires potential f...
09-03 11:30
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, HLVX, AVDX on Behalf of Shareholders
NEW YORK, Aug. 20, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
08-20 23:02
